Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
AstraZeneca
Dow
Colorcon
Moodys

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Sipuleucel-T

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Sipuleucel-T: Patents, clinical trial progress, indications

Sipuleucel-T is an investigational drug.

There have been 20 clinical trials for Sipuleucel-T. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2013.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Adenocarcinoma, and Carcinoma. The leading clinical trial sponsors are Dendreon, Duke University, and The University of Texas Health Science Center, Houston.

There are sixteen US patents protecting this investigational drug and one hundred and thirty-six international patents.

Recent Clinical Trials for Sipuleucel-T
TitleSponsorPhase
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerDendreonPhase 1
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerGenentech, Inc.Phase 1
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerUniversity of HawaiiPhase 1

See all Sipuleucel-T clinical trials

Clinical Trial Summary for Sipuleucel-T

Top disease conditions for Sipuleucel-T
Top clinical trial sponsors for Sipuleucel-T

See all Sipuleucel-T clinical trials

US Patents for Sipuleucel-T

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sipuleucel-T   Start Trial Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
Sipuleucel-T   Start Trial RNA-biomarkers for diagnosis of prostate cancer FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG (Munchen, CN)   Start Trial
Sipuleucel-T   Start Trial RNA-biomarkers for diagnosis of prostate cancer FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWAND (Munchen, DE)   Start Trial
Sipuleucel-T   Start Trial Prostate cancer classification ALMAC DIAGNOSTICS LIMITED (GB)   Start Trial
Sipuleucel-T   Start Trial Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome Dendreon Corporation (Seattle, WA)   Start Trial
Sipuleucel-T   Start Trial Compounds for use in treating or preventing cancerous diseases BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sipuleucel-T

Drugname Country Document Number Estimated Expiration Related US Patent
Sipuleucel-T World Intellectual Property Organization (WIPO) 2012142208 2031-04-13   Start Trial
Sipuleucel-T European Patent Office 2878678 2033-12-02   Start Trial
Sipuleucel-T European Patent Office 3077530 2033-12-02   Start Trial
Sipuleucel-T European Patent Office 3077531 2033-12-02   Start Trial
Sipuleucel-T European Patent Office 3077535 2033-12-02   Start Trial
Sipuleucel-T European Patent Office 3077536 2033-12-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Medtronic
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.